Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1951]

Perioperative anti–PD-L1 therapy improves event-free survival in resectable...

Prof Yi-Long Wu - Guangdong Lung Cancer Institute, Guangzhou, China

Perioperative anti–PD-L1 therapy improves event-free survival in resectable NSCLC with ctDNA-based risk stratification ( Prof Yi-Long Wu - Guangdong Lung Cancer Institute, Guangzhou, China )

Denikitug shows immune activation and early anti-tumour activity in advanced...

Dr Bruno Bockorny - Beth Israel Deaconess Medical Center, Boston, USA

Denikitug shows immune activation and early anti-tumour activity in advanced solid tumour ( Dr Bruno Bockorny - Beth Israel Deaconess Medical Center, Boston, USA )

Zedoresertib plus lunresertib shows promising tumour shrinkage in CCNE1...

Dr Timothy Yap - UT MD Anderson Cancer Center, Houston, USA

Zedoresertib plus lunresertib shows promising tumour shrinkage in CCNE1-amplified and FBXW7-mutant cancers ( Dr Timothy Yap - UT MD Anderson Cancer Center, Houston, USA )

The potential of T-cell engagers in SCLC treatment

Dr Luis Paz-Ares - 12 de Octubre University Hospital, Madrid, Spain

The potential of T-cell engagers in SCLC treatment ( Dr Luis Paz-Ares - 12 de Octubre University Hospital, Madrid, Spain )

EAU 2026: Updates in NMIBC

Dr Francesco Soria, Prof Jonathan Aning, Dr Antoni Vilaseca and Prof Alexandra...

EAU 2026: Updates in NMIBC ( Dr Francesco Soria, Prof Jonathan Aning, Dr Antoni Vilaseca and Prof Alexandra Masson-Lecomte )

Enzalutamide plus radium-223 extends survival in bone metastatic prostate cancer

Dr Enrique Gallardo - Parc Taulí University Hospital, Sabadell, Spain

Enzalutamide plus radium-223 extends survival in bone metastatic prostate cancer ( Dr Enrique Gallardo - Parc Taulí University Hospital, Sabadell, Spain )

ASCO GU 2026: Updates in renal cancer

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo'...

ASCO GU 2026: Updates in renal cancer ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )

ASCO GU 2026: Updates in bladder cancer

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo'...

ASCO GU 2026: Updates in bladder cancer ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )

ASCO GU 2026: Updates in metastatic prostate cancer

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo'...

ASCO GU 2026: Updates in metastatic prostate cancer ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )

ASCO GU 2026: Updates in localised prostate cancer

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo'...

ASCO GU 2026: Updates in localised prostate cancer ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )

ASCO GU 2026: Latest updates in mRCC

Dr Toni Choueiri, Prof Viktor Grünwald, Dr Stephanie Berg, Dr Cristina Suárez...

ASCO GU 2026: Latest updates in mRCC ( Dr Toni Choueiri, Prof Viktor Grünwald, Dr Stephanie Berg, Dr Cristina Suárez and Dr Guillermo de Velasco )

Epcoritamab plus rituximab and lenalidomide improves efficacy in relapsed or...

Dr Lorenzo Falchi - Memorial Sloan Kettering Cancer Center, New York, USA

$Epcoritamab plus rituximab and lenalidomide improves efficacy in relapsed or refractory follicular lymphoma ( Dr Lorenzo Falchi - Memorial Sloan Kettering Cancer Center, New York, USA )$

More from ecancer